Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations

Xiangyan Li(Changchun University of Chinese Medicine), Wen‐Chin Huang(Scripps Research Institute)
Oncotarget
October 16, 2015
Cited by 74


Related Papers